BR0014003A - Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra - Google Patents
Tratamento de combinação com compostos de diaril sufonil uréia e il-1raInfo
- Publication number
- BR0014003A BR0014003A BR0014003-1A BR0014003A BR0014003A BR 0014003 A BR0014003 A BR 0014003A BR 0014003 A BR0014003 A BR 0014003A BR 0014003 A BR0014003 A BR 0014003A
- Authority
- BR
- Brazil
- Prior art keywords
- sufonil
- urea
- compounds
- combination treatment
- diaryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Patente de Invenção: "TRATAMENTO DE COMBINAçãO COM COMPOSTOS DE DIARIL SUFONIL URéIA E IL-1RA". A invenção refere-se com métodos e composições para tratar e prevenir estados de doença mediados pela interleucina 1 (IL-1). Os métodos e composições utilizam um polipeptídeo antagonista do receptor da interleucina 1 (IL-1 ra) ou uma variante deste em combinação com um agente não esteroidal de inibição do processamento e liberação de IL-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15401099P | 1999-09-14 | 1999-09-14 | |
PCT/IB2000/001192 WO2001019390A1 (en) | 1999-09-14 | 2000-08-28 | Combination treatment with il-1ra and diaryl sulphonyl urea compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0014003A true BR0014003A (pt) | 2002-05-21 |
Family
ID=22549650
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0014003-1A BR0014003A (pt) | 1999-09-14 | 2000-08-28 | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP1214087A1 (pt) |
JP (1) | JP2003509378A (pt) |
AR (1) | AR033650A1 (pt) |
AU (1) | AU6464400A (pt) |
BR (1) | BR0014003A (pt) |
CA (1) | CA2383026A1 (pt) |
CO (1) | CO5190701A1 (pt) |
EC (1) | ECSP003652A (pt) |
GT (1) | GT200000155A (pt) |
PA (1) | PA8502901A1 (pt) |
PE (1) | PE20010685A1 (pt) |
TN (1) | TNSN00183A1 (pt) |
WO (1) | WO2001019390A1 (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2557910C (en) | 2004-04-02 | 2012-05-29 | Amgen Inc. | Methods of reducing aggregation of il-1ra |
WO2008129288A2 (en) * | 2007-04-19 | 2008-10-30 | Boehringer Ingelheim International Gmbh | Disulfonamides useful in the treatment of inflammation |
PE20221627A1 (es) | 2015-02-16 | 2022-10-19 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos |
CA3014487A1 (en) | 2016-02-16 | 2017-08-24 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Sulfonylureas and related compounds and use of same |
AU2017254522B2 (en) | 2016-04-18 | 2021-09-23 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
CA3047336A1 (en) | 2017-01-23 | 2018-07-26 | Jecure Therapeutics, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
JP7072586B2 (ja) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
US11370776B2 (en) | 2017-07-07 | 2022-06-28 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
RS62910B1 (sr) | 2017-07-07 | 2022-03-31 | Inflazome Ltd | Nova jedinjenja sulfonamid karboksamida |
EP3658539B1 (en) | 2017-07-24 | 2024-02-21 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
UY37847A (es) * | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
CN111107903A (zh) | 2017-08-15 | 2020-05-05 | 英夫拉索姆有限公司 | 新颖的磺酰胺羧酰胺化合物 |
US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
US11884645B2 (en) | 2018-03-02 | 2024-01-30 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
EP3759103A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
GB201806578D0 (en) * | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
CN112584899A (zh) | 2018-07-03 | 2021-03-30 | 诺华股份有限公司 | Nlrp调节剂 |
BR112021001012A2 (pt) | 2018-07-20 | 2021-04-20 | F. Hoffmann-La Roche Ag | compostos de sulfonilureia como inibidores da atividade de interleucina-1 |
JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
EA202191968A1 (ru) | 2019-01-14 | 2021-11-16 | Кадила Хелзкэр Лимитед | Новые замещенные производные сульфонилмочевины |
CA3171969A1 (en) * | 2020-05-25 | 2021-12-02 | Beijing Vdjbio Co., Ltd. | An interleukin-1 receptor antagonist and a fusion protein containing the same |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874424A (en) * | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
TR199901816T2 (xx) * | 1997-01-29 | 1999-11-22 | Pfizer Inc | S�lfonil �re t�revleri, bunlar�n interl�kin-1 aktivitesinin kontrol�nde kullan�mlar�. |
US6015790A (en) * | 1997-10-06 | 2000-01-18 | Basf Aktiengesellschaft | Methods and compositions for treating rheumatoid arthritis |
EP0987552A3 (en) * | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
-
2000
- 2000-08-28 CA CA002383026A patent/CA2383026A1/en not_active Abandoned
- 2000-08-28 EP EP00951799A patent/EP1214087A1/en not_active Withdrawn
- 2000-08-28 BR BR0014003-1A patent/BR0014003A/pt not_active IP Right Cessation
- 2000-08-28 JP JP2001523022A patent/JP2003509378A/ja active Pending
- 2000-08-28 AU AU64644/00A patent/AU6464400A/en not_active Abandoned
- 2000-08-28 WO PCT/IB2000/001192 patent/WO2001019390A1/en not_active Application Discontinuation
- 2000-09-05 CO CO00066883A patent/CO5190701A1/es not_active Application Discontinuation
- 2000-09-11 PA PA20008502901A patent/PA8502901A1/es unknown
- 2000-09-12 AR ARP000104779A patent/AR033650A1/es not_active Application Discontinuation
- 2000-09-12 PE PE2000000942A patent/PE20010685A1/es not_active Application Discontinuation
- 2000-09-12 EC EC2000003652A patent/ECSP003652A/es unknown
- 2000-09-13 TN TNTNSN00183A patent/TNSN00183A1/fr unknown
- 2000-09-14 GT GT200000155A patent/GT200000155A/es unknown
Also Published As
Publication number | Publication date |
---|---|
EP1214087A1 (en) | 2002-06-19 |
JP2003509378A (ja) | 2003-03-11 |
AU6464400A (en) | 2001-04-17 |
CO5190701A1 (es) | 2002-08-29 |
AR033650A1 (es) | 2004-01-07 |
CA2383026A1 (en) | 2001-03-22 |
WO2001019390A1 (en) | 2001-03-22 |
ECSP003652A (es) | 2002-04-23 |
PA8502901A1 (es) | 2002-02-21 |
TNSN00183A1 (fr) | 2005-11-10 |
GT200000155A (es) | 2002-03-08 |
PE20010685A1 (es) | 2001-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0014003A (pt) | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra | |
BR0213817A (pt) | Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9 | |
BR9913945A (pt) | Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos | |
BR9913319A (pt) | Composições e métodos para tratamento de doenças mitocondriais | |
BR9808948A (pt) | Composição de confeitaria | |
BR9911666A (pt) | Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica | |
BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
BR9809968A (pt) | Aplicação de derivados tiazolidinadiona no tratamento da pcos e diabetes gestacional | |
BR9812753A (pt) | Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica | |
BR0312421A (pt) | Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos | |
BR0111196A (pt) | Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus | |
BR0212042A (pt) | Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto | |
BR0000003A (pt) | Azalidas e métodos de preparação das mesmas | |
BR0107147A (pt) | Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
EA200100870A1 (ru) | Композиции-ингибиторы циклооксигеназы-2 с быстро наступающим терапевтическим действием | |
BRPI0307351B8 (pt) | composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto | |
AR002974A1 (es) | Utilización de por lo menos un antagonista de cgrppara la preparación de una composición cosmética, farmacéutica y/o dermatológica para tratar las manchas rojas cutáneas de origen neurógeno, composición obtenida y procedimiento de tratamiento cosmético empleando dicho antagonista. | |
TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
BR9811556A (pt) | Terapia de combinação compreendendo atorvastatina e um agente anti-hipertensivo | |
BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
RS50091B (sr) | Upotreba retigabina u lečenju neuropatskog bola | |
BR0010209A (pt) | Composições para o tratamento de desordens do esÈfago | |
HUP0203586A2 (hu) | Szerotonin újrafelvétel inhibitorának, valamint 5-ht2c antagonistának, inverz agonistának vagy részleges agonistának a kombinációja | |
BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008. |